Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

N. Kennedy; L. Berger; J. Curram; R. Fox; J. Gutmann; G. M. Kisyombe; F. I. Ngowi; A. R.C. Ramsay; A. O.S. Saruni; N. Sam; G. Tillotson; L. O. Uiso; M. Yates; S. H. Gillespie

doi:10.1093/clinids/22.5.827

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

N. Kennedy, L. Berger, J. Curram, R. Fox, J. Gutmann, G. M. Kisyombe, F. I. Ngowi, A. R.C. Ramsay, A. O.S. Saruni, N. Sam, G. Tillotson, L. O. Uiso, M. Yates, S. H. Gillespie^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV- infected patients.

Original language	English
Pages (from-to)	827-833
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	22
Issue number	5
DOIs	https://doi.org/10.1093/clinids/22.5.827
Publication status	Published - 1 Jan 1996

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

AIDS-Related Opportunistic Infections/drug therapy
Adult
Anti-Infective Agents/administration & dosage
Antitubercular Agents/administration & dosage
Ciprofloxacin/administration & dosage
Ethambutol/administration & dosage
Female
HIV-1
Humans
Isoniazid/administration & dosage
Male
Middle Aged
Pyrazinamide/administration & dosage
Rifampin/administration & dosage
Time Factors
Tuberculosis, Pulmonary/complications

Access to Document

10.1093/clinids/22.5.827

Handle.net

Persistent link

Cite this

Kennedy, N., Berger, L., Curram, J., Fox, R., Gutmann, J., Kisyombe, G. M., Ngowi, F. I., Ramsay, A. R. C., Saruni, A. O. S., Sam, N., Tillotson, G., Uiso, L. O., Yates, M., & Gillespie, S. H. (1996). Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases, 22(5), 827-833. https://doi.org/10.1093/clinids/22.5.827

@article{b08f7e9b1532408ab89cf6b2f842a632,

title = "Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis",

abstract = "The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV- infected patients.",

keywords = "AIDS-Related Opportunistic Infections/drug therapy, Adult, Anti-Infective Agents/administration \& dosage, Antitubercular Agents/administration \& dosage, Ciprofloxacin/administration \& dosage, Ethambutol/administration \& dosage, Female, HIV-1, Humans, Isoniazid/administration \& dosage, Male, Middle Aged, Pyrazinamide/administration \& dosage, Rifampin/administration \& dosage, Time Factors, Tuberculosis, Pulmonary/complications",

author = "N. Kennedy and L. Berger and J. Curram and R. Fox and J. Gutmann and Kisyombe, \{G. M.\} and Ngowi, \{F. I.\} and Ramsay, \{A. R.C.\} and Saruni, \{A. O.S.\} and N. Sam and G. Tillotson and Uiso, \{L. O.\} and M. Yates and Gillespie, \{S. H.\}",

year = "1996",

month = jan,

day = "1",

doi = "10.1093/clinids/22.5.827",

language = "English",

volume = "22",

pages = "827--833",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

Kennedy, N, Berger, L, Curram, J, Fox, R, Gutmann, J, Kisyombe, GM, Ngowi, FI, Ramsay, ARC, Saruni, AOS, Sam, N, Tillotson, G, Uiso, LO, Yates, M & Gillespie, SH 1996, 'Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis', Clinical Infectious Diseases, vol. 22, no. 5, pp. 827-833. https://doi.org/10.1093/clinids/22.5.827

TY - JOUR

T1 - Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

AU - Kennedy, N.

AU - Berger, L.

AU - Curram, J.

AU - Fox, R.

AU - Gutmann, J.

AU - Kisyombe, G. M.

AU - Ngowi, F. I.

AU - Ramsay, A. R.C.

AU - Saruni, A. O.S.

AU - Sam, N.

AU - Tillotson, G.

AU - Uiso, L. O.

AU - Yates, M.

AU - Gillespie, S. H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV- infected patients.

AB - The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV- infected patients.

KW - AIDS-Related Opportunistic Infections/drug therapy

KW - Adult

KW - Anti-Infective Agents/administration & dosage

KW - Antitubercular Agents/administration & dosage

KW - Ciprofloxacin/administration & dosage

KW - Ethambutol/administration & dosage

KW - Female

KW - HIV-1

KW - Humans

KW - Isoniazid/administration & dosage

KW - Male

KW - Middle Aged

KW - Pyrazinamide/administration & dosage

KW - Rifampin/administration & dosage

KW - Time Factors

KW - Tuberculosis, Pulmonary/complications

UR - https://www.scopus.com/pages/publications/9344271132

U2 - 10.1093/clinids/22.5.827

DO - 10.1093/clinids/22.5.827

M3 - Article

C2 - 8722940

AN - SCOPUS:9344271132

SN - 1058-4838

VL - 22

SP - 827

EP - 833

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

Abstract

UN SDGs

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this